The Business Research Company’s report on the Emphysema Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the emphysema industry?
The increasing prevalence of respiratory infections is expected to propel the growth of the emphysema market going forward. Respiratory infections refer to infections that affect the respiratory system, including the sinuses, throat, airways, and lungs. Growing respiratory infections are due to pollution, climate change, antimicrobial resistance, urbanization, and evolving pathogens. Respiratory infections accelerate emphysema progression by causing inflammation, tissue damage, and increased airway obstruction, worsening lung function. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, the U.S. reported 9,633 tuberculosis (TB) cases, a 15.6% rise from 8,332 in 2022, with the incidence rate increasing 15.0% from 2.5 to 2.9 per 100,000 persons. Therefore, the increasing prevalence of respiratory infections is driving the growth of the emphysema market.
Access Your Free Sample of the Global Emphysema Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp
What is the estimated market size of the emphysema sector by 2029, based on current forecasts?
The emphysema market size has grown strongly in recent years. It will grow from $4.74 billion in 2024 to $4.99 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to the growing prevalence of respiratory diseases, the growing aging population, increasing smoking, increasing air pollution, increasing government initiatives, and an increased population with tobacco smoking.
The emphysema market size is expected to see steady growth in the next few years. It will grow to $6.05 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing healthcare spending, rising environmental pollution, increasing demand for diagnostic medical devices, increasing vehicular traffic, and growing demand for minimally invasive procedures. Major trends in the forecast period include new inhalation devices, strategic partnerships, personalized medicine, telemedicine, advancements in inhalation therapies, and medical advancements.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp
Who are the top players in the emphysema market?
Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., Olympus Corporation, ResMed Inc., Chiesi Farmaceutici S.p.A., University of Chicago Medicine (UChicago Medicine), Hikma Pharmaceuticals PLC, United Therapeutics Corporation, VIDA Diagnostics Inc., Kamada Limited, Pulmonx Corporation, Mereo BioPharma Group PLC, Uptake Medical Corporation, Verona Pharma PLC.
What are the major trends in the emphysema market?
Major companies operating in the emphysema market are focusing on medical innovations, such as inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4, to provide patients with advanced treatments that improve lung function, reduce inflammation, and enhance overall management of the disease, fostering better respiratory health and quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 is a medication that targets and blocks both phosphodiesterase enzymes in the lungs, which helps relax the airways and reduce inflammation, improving breathing in conditions like chronic obstructive pulmonary disease. For instance, in June 2024, Verona Pharma plc, a UK-based pharma company, launched Ohtuvayre (ensifentrine), the first inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a US-based federal agency, for the maintenance treatment of chronic obstructive pulmonary diseases like emphysema, marking the first novel inhaled therapy in over 20 years. The drug, which combines bronchodilator and anti-inflammatory effects, is to be available through specialty pharmacies.
Which geography holds the highest emphysema market share?
North America was the largest region in the emphysema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report
How do different segments contribute to the overall expansion of the emphysema market?
The emphysema market covered in this report is segmented –
1) By Type: Centrilobular, Panlobular
2) By Treatment: Medication, Therapy, Surgery, Other Treatments
3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis
4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications
5) By End-user: Hospitals And Clinics, Surgical Center, Other End-users
Subsegments:
1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema
2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21956
What defines the structure and scope of the emphysema market?
Emphysema is a chronic lung disease that damages the air sacs (alveoli) in the lungs, leading to difficulty in breathing. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by smoking or long-term exposure to air pollutants. As the alveoli become weakened and lose their elasticity, air gets trapped, making it harder for the lungs to expel carbon dioxide and take in fresh oxygen. This results in shortness of breath, chronic cough, and reduced lung function over time.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
